Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Raval, Mihir
VAYHIT3, NCT05885555: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies	Active, not recruiting	2	41	Europe, US, RoW	Ianalumab, VAY736	Novartis Pharmaceuticals	Primary Immune Thrombocytopenia (ITP)	02/25	03/29
NCT04782687: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma	Active, not recruiting	2	73	US	Selinexor, Xpovio, Dexamethasone Oral, Daratumumab, Darzalex, Lenalidomide, Revlimid	US Oncology Research, Karyopharm Therapeutics Inc	Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma	05/26	05/26
Faruol, Josephine
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, Japan, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers	Active, not recruiting	2/3	150	US	CTX-009, Paclitaxel	Compass Therapeutics	Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer	07/25	12/25
GEMINI-NSCLC, NCT05236114: NSCLC Biomarker Study	Recruiting	N/A	1200	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/29	06/29
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Raval, Mihir
VAYHIT3, NCT05885555: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies	Active, not recruiting	2	41	Europe, US, RoW	Ianalumab, VAY736	Novartis Pharmaceuticals	Primary Immune Thrombocytopenia (ITP)	02/25	03/29
NCT04782687: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma	Active, not recruiting	2	73	US	Selinexor, Xpovio, Dexamethasone Oral, Daratumumab, Darzalex, Lenalidomide, Revlimid	US Oncology Research, Karyopharm Therapeutics Inc	Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma	05/26	05/26
Faruol, Josephine
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, Japan, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers	Active, not recruiting	2/3	150	US	CTX-009, Paclitaxel	Compass Therapeutics	Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer	07/25	12/25
GEMINI-NSCLC, NCT05236114: NSCLC Biomarker Study	Recruiting	N/A	1200	US	Observation	Tempus AI, AstraZeneca	Non-Small Cell Lung Cancer	06/29	06/29
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37